 The U.S.-listed shares of Alterity Therapeutics Ltd. rocketed 129.6 on massive volume in morning trading Monday, enough to be the biggest gainer among those listed on major U.S. exchanges, after the Australia-based drug maker announced the allowance of a new patent for next generation compounds to treat neurodegenerative diseases. 